GeNeuro and Verily Collaborate to Advance Long-COVID Research
19 Octobre 2023 - 8:00AM
Business Wire
Partnership to combine GeNeuro’s expertise
in HERVs with Verily’s Immune Profiler and Workbench platforms to
investigate biomarkers related to HERV-W
Regulatory News:
GeNeuro (Euronext Paris: CH0308403085 - GNRO), a
biopharmaceutical company developing novel treatments for
neurodegenerative and autoimmune diseases, announced a
collaboration with Verily, an Alphabet precision health technology
company, to investigate biomarkers related to activation of the
proinflammatory HERV-W envelope protein (W-ENV) in SARS-CoV-2
infection.
Through this collaboration, GeNeuro will partner with Verily to
build on results published earlier this year in Cell Press, which
evidenced the in vitro activation of HERV-W by SARS-CoV-2 in
susceptible individuals and the correlation between W-ENV protein
levels in serum and lymphocytes with COVID-19 severity.
“Our research indicates that W-ENV contributes to COVID-19
disease severity and may explain manifestations of long-COVID,”
said Dr. Hervé Perron, Chief Scientific Officer of GeNeuro.
“This collaboration with Verily advances GeNeuro’s ambitions to
treat patients with long-COVID using a personalized medicine
approach through biomarker identification of those more likely to
present with severe disease.”
Verily will provide high-resolution multi-omic data generated
from COVID patient samples using Immune Profiler, Verily’s
state-of-the-art immune mapping platform, and high-powered data
analysis using Workbench, a secure research environment for
governing and analyzing multimodal biomedical data. Both solutions
are part of Verily’s broader suite of products built to deliver on
the promise of precision health and harness the power of richer,
more diverse datasets to accelerate medical research.
“We are excited to partner with GeNeuro to advance our shared
belief that identification of actionable biomarkers early in
disease can advance precision health and save lives,” said
Charlie Kim, Head of Molecular Science at Verily. “This
could be an important step toward earlier, more targeted
interventions for patients with long-COVID.”
About GeNeuro
GeNeuro‘s mission is to develop safe and effective treatments
against neurological disorders and autoimmune diseases, such as
multiple sclerosis, by neutralizing causal factors encoded by
HERVs, which represent 8% of human DNA.
For more information, visit: www.geneuro.com.
About Verily
Verily is an Alphabet health technology company focused on
research, care, and health financing to deliver on the promise of
precision health and help people live healthier lives. We are
uniquely positioned at the intersection of technology, data
science, and healthcare to create tools to accelerate evidence
generation, products to enable more personalized care, and
approaches to make costs more predictable. For more information,
please visit: verily.com.
Disclaimer
This press release contains certain forward - looking statements
and estimates concerning GeNeuro’s financial condition, operating
results, strategy, projects and future performance and the markets
in which it operates. Such forward-looking statements and estimates
may be identified by words such as “anticipate,” “believe,” “can,”
“could,” “estimate,” “expect,” “intend,” “is designed to,” “may,”
“might,” “plan,” “potential,” “predict,” “objective,” “should,” or
the negative of these and similar expressions. They incorporate all
topics that are not historical facts. Forward looking statements,
forecasts and estimates are based on management’s current
assumptions and assessment of risks, uncertainties and other
factors, known and unknown, which were deemed to be reasonable at
the time they were made but which may turn out to be incorrect.
Events and outcomes are difficult to predict and depend on factors
beyond the Company’s control. Consequently, the actual results,
financial condition, performances and/or achievements of GeNeuro or
of the industry may turn out to differ materially from the future
results, performances or achievements expressed or implied by these
statements, forecasts and estimates. Owing to these uncertainties,
no representation is made as to the correctness or fairness of
these forward-looking statements, forecasts and estimates.
Furthermore, forward-looking statements, forecasts and estimates
speak only as of the date on which they are made, and GeNeuro
undertakes no obligation to update or revise any of them, whether
as a result of new information, future events or otherwise, except
as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231018266431/en/
GeNeuro Jesús Martin-Garcia Chairman and CEO +41 22 552
4800 investors@geneuro.com
NewCap (France) Louis-Victor Delouvrier +33 1 44 71 98 52
Arthur Rouillé (media) +33 1 44 71 94 98 geneuro@newcap.eu
Verily Steven Cooper Head of Media Relations +1 (646) 358
2765 sjcoop@verily.com
GeNeuro (EU:GNRO)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
GeNeuro (EU:GNRO)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024